Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
Open Access
- 1 August 2008
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 112 (3), 610-618
- https://doi.org/10.1182/blood-2008-01-135319
Abstract
CD4+CD25highFoxP3+ regulatory T (Treg) cells limit antigen-specific immune responses and are a cause of suppressed anticancer immunity. In preclinical and clinical studies, we assessed the immune consequences of FoxP3+ Treg-cell depletion in patients with advanced malignancies. We demonstrated that a CD25high targeting immunotoxin (denileukin diftitox) depleted FoxP3+ Treg cells, decreased Treg-cell function, and enhanced antigen-specific T-cell responses in vitro. We then attempted to enhance antitumor immune responses in patients with carcinoembryonic antigen (CEA)–expressing malignancies by Treg-cell depletion. In a pilot study (n = 15), denileukin diftitox, given as a single dose or repeated dosing, was followed by immunizations with dendritic cells modified with the fowlpox vector rF-CEA(6D)-TRICOM. By flow cytometric analysis, we report the first direct evidence that circulating CD4+CD25highFoxP3+ Treg cells are depleted after multiple doses of denileukin diftitox. Earlier induction of, and overall greater exposure to, the T-cell response to CEA was observed in the multiple-dose group, but not the single-dose group. These results indicate the potential for combining Treg-cell depletion with anticancer vaccines to enhance tumor antigen-specific immune responses and the need to explore dose and schedule of Treg depletion strategies in optimiz-ing vaccine efforts. This trial was registered at www.clinicaltrials.gov as no. NCT00128622.This publication has 27 references indexed in Scilit:
- IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunityBlood, 2007
- Immunoregulatory T cells in tumor immunityCurrent Opinion in Immunology, 2004
- Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral toleranceSeminars in Immunology, 2004
- CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide VaccinationThe Journal of Immunology, 2003
- Increase of regulatory T cells in the peripheral blood of cancer patients.2003
- CD4+CD25+ suppressor T cells: more questions than answersNature Reviews Immunology, 2002
- Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell ProliferationThe Journal of Immunology, 2002
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation toleranceImmunological Reviews, 2001
- Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2001